Posphatidyl choline (lecithin) by mouth, is known to increase serum choline levels more efficiently than choline chloride (Wurtman et al. 1977) . The administration of lecithin (24 g/day) was reported by Barbeau (1978) as being effective in improving speech, balance and movement disorders in eight patients with Friedreich's ataxia (F.A.) . Clinical improvement with lecithin was assumed to be consecutive to a sequential increase in serum choline, brain choline and finally brain acetyl-choline levels or to the correction of a membrane defect. Physostigmine, a cholinesterase inhibitor which enhances brain acetylcholine levels, has also been reported by Rodriguez-Budelli et al. (1978) to improve ataxia in patients with spinocerebellar disorders with or without pyruvate oxidation defects.
The present study was initiated when some younger patients with F.A. expressed the desire to go on a trial of oral lecithin. We decided to obtain some information on the biochemical effects of lecithin, assuming that any significant increase in the synthesis of acetyl-choline would mean an accelerated utilization of acetyl-CoA radicals and possible changes in the activity of the pyruvate dehydrogenase complex. This hypothesis was based on previous reports by our group ) and other investigators ) of a defective lipoamide dehydrogenase (LAD), the third component of the pyruvate dehydrogenase complex in patients with F.A. and other F.A.-like forms of familial spino-cerebellar ataxias. Fasting serum (10ml) obtained from controls and patients was frozen at -80° C in one ml. aliquots and assayed within one month for lipoamide dehydrogenase activity (LAD). Repeat serum samples were obtained from seven of the nine original patients and one additional patient after three months on oral phosphatidyl choline (lecithine, LALCO, Ltd. Montreal) at a dose of 3.2 g three times a day. Four patients were also available for blood sampling one month after the start of lecithin and two of them elected not to pursue their treatment thereafter. Measurement of LAD activity and kinetic studies were carried out using freshly thawed serum and freshly prepared reagents as previously suggested (Melancon et al. 1978b ). Standard runs using freshly thawed serum from the same control individual were made before every determination of LAD activity. Optical density readings averaged .039 ± .003 units/10 min/0.05 ml of serum (Range, .032 -.044) for a total of forty LAD determinations over a period of three months. Total LAD activity in serum was determined according to Pelley et al. (1976) . Kinetic studies were performed using lipoamide at concentrations of 0.4 mM to 6 mM and NAD at concentrations of 0.05 mM to 3.0 mM. Inhibition of LAD activity by added NADH (Ki) was estimated with NADH at concentrations of 0.1 mM to 0.4 mM. Michaelis-Menten constants (Km) were calculated by linear regression from the linear portion of Lineweaver-Burk plots. Maximal enzyme velocities (Vmax) were determined in the same manner and for the purpose of illustration, were reported in optical density units (O.D.). Conversion into LAD U/liter of serum was done by multiplying the O.D. by 322 x 103.
MATERIALS AND METHODS

RESULTS
Seven of the nine patients treated with lecithin reported some degree of clinical improvement. By standard neurological evaluation it was found that these patients had improved their muscular strength and physical resistance in a qualitative rather than quantitative manner. Two patients experienced subjective deterioration after one month of therapy and elected to cease their treatment.
The effects of lecithin on LAD activity and kinetics in serum of patients with F.A. are illustrated in figures 1 and 2. The most striking effects appeared to be the reduction in Km and Vmax of LAD towards lipoamide in three patients ( fig. 1 center and right) and the statistically significant reduction in LAD inhibition by NADH ( fig. 2 right and table I) in patients with F.A. after three months of lecithin therapy.
The mean activity of LAD in serum as function of age of patient and controls is illustrated in figure 3.
DISCUSSION
Our results provide some evidence that the subjective clinical improvement observed with lecithin in patients with F.A. may occur through biochemical changes other than previously thought. We presume with others (Growdon et al. 1977 ) that part of the clinical success was due to an improved availability of acetyl-choline from exogenous doses of choline precursor (lecithin). However, we have evidence that lecithin or some unknown metabolite of lecithin displayed some action prior to acetylcholine synthesis and possibly at the enzyme level itself.
The exact origin of LAD in serum is still unknown, although Pelley et al. (1976) provided evidence that liver could account for most of the enzyme recovered in serum. Our kinetic studies on serum and previous work in fibroblasts (Melancon et al. 1978a, b) were not in favor of the presence of more than one component of LAD, as reported for platelets . However, three of our nine patients displayed higher than control Km for lipoamide before lecithin and one after lecithin (the only control subject with high Km for lipoamide was a 38-year-old apparently healthy cousin of two patients with F.A.). These data would be in agreement with the results of Kark et al. (1980) who reported an increased Km for lipoamide (in platelets) in families of patients with a recessive form of ataxia. However, there is a marked difference between lipoamide Km values in platelets (low = .056 mM; high = .147 mM) and serum (.73 mM) which prevent us from comparing the results in an adequate way. The effect of lecithin on LAD inhibition by exogenous NADH cannot be adequately explained at the present time. This decrease in the concentration of NADH necessary to bring out a 50% lowering in serum LAD activity may be due to factors present in serum or to enzymatic changes. We have not yet attempted to elucidate the origin of this modification. Another unexpected finding was disclosed when serum LAD activity were plotted according to age. It was found that serum LAD activity was higher in younger patients with F.A., than in older control subjects. This observation is, however, not incompatible with previous reports of a decreased serum LAD activity (Melancon et al. 1977; Filla et al. 1978) in older patients with F.A. We are presently investigating the effect of lecithin on LAD activity, enzyme kinetics and objective parameters of physical performance in patients with F.A. and age-matched controls in a double-blind study. We hope to be able to answer some of the previously discussed but unresolved questions at the completion of this second study.
